Trial Profile
A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 16 Jun 2022 Results of pharmacokinetics and exposure response analysis from Phase 1b Study and Phase 3 trials (CLL14 and GP28331) published in the Advances in Therapy
- 07 Jan 2020 Status changed from active, no longer recruiting to completed.
- 18 Nov 2019 Planned End Date changed from 23 Aug 2019 to 31 Dec 2019.